Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Allez

Showing results (121-130 of 205) with videos related to

Pageof 21
Sort By:
Journal of Crohn'S & Colitis|March 20, 2023
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's DiseaseMatthieu Allez, Bruce E Sands, Brian G Feagan, et al.
Rheumatology (Oxford, England)|September 12, 2018
Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel diseaseSayam Dubash, Thiraupathy Marianayagam, Ilaria Tinazzi, et al.
Journal of Crohn'S & Colitis|January 12, 2018
Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMTJohn A Snowden, Julián Panés, Tobias Alexander, et al.
Gastroenterology|April 2, 2013
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel diseaseLaurent Beaugerie, Magali Svrcek, Philippe Seksik, et al.
Journal of Crohn'S & Colitis|July 15, 2025
Susceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancerJanine Kövilein, Adam Sorbie, Sevana Khaloian, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Gastroenterology|August 14, 2012
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's diseasePierre Desreumaux, Arnaud Foussat, Matthieu Allez, et al.
Gut|February 23, 2019
T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrenceMatthieu Allez, Claire Auzolle, Marjolaine Ngollo, et al.
Bulletin Du Cancer|October 17, 2020
[Crohn's disease and autologous hemapoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Mathieu Puyade, Xavier Treton, Laurent Alric, et al.
Gastroenterology|December 18, 2018
Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function MutationMarianna Parlato, Fabienne Charbit-Henrion, Elie Abi Nader, et al.
Pageof 21

Showing results (121-130 of 205) with videos related to

Sort By:
Pageof 21
Journal of Crohn'S & Colitis|March 20, 2023
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's DiseaseMatthieu Allez, Bruce E Sands, Brian G Feagan, et al.
Rheumatology (Oxford, England)|September 12, 2018
Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel diseaseSayam Dubash, Thiraupathy Marianayagam, Ilaria Tinazzi, et al.
Journal of Crohn'S & Colitis|January 12, 2018
Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMTJohn A Snowden, Julián Panés, Tobias Alexander, et al.
Gastroenterology|April 2, 2013
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel diseaseLaurent Beaugerie, Magali Svrcek, Philippe Seksik, et al.
Journal of Crohn'S & Colitis|July 15, 2025
Susceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancerJanine Kövilein, Adam Sorbie, Sevana Khaloian, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Gastroenterology|August 14, 2012
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's diseasePierre Desreumaux, Arnaud Foussat, Matthieu Allez, et al.
Gut|February 23, 2019
T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrenceMatthieu Allez, Claire Auzolle, Marjolaine Ngollo, et al.
Bulletin Du Cancer|October 17, 2020
[Crohn's disease and autologous hemapoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Mathieu Puyade, Xavier Treton, Laurent Alric, et al.
Gastroenterology|December 18, 2018
Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function MutationMarianna Parlato, Fabienne Charbit-Henrion, Elie Abi Nader, et al.
Pageof 21